Date: 2018-02-05

Type of information: Nomination

Compound: member of the scientific advisory board

Company: Orchard Therapeutics (UK)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement: nomination

Action mechanism:



  • • On February 5, 2018, Orchard Therapeutics announced the appointment of Harry Malech, M.D., to its scientific advisory board (SAB). Dr. Malech will be contributing his time and expertise ad honorem. Dr. Malech is a globally recognized expert in primary immune deficiencies (PIDs) and gene therapy. He is currently deputy chief of the Laboratory of Clinical Immunology and Microbiology (LCIM) and chief of the Genetic Immunotherapy Section (GIS) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), where he leads research and clinical development of gene therapy and hematopoietic stem cell transplantation approaches.
  • Dr. Malech received his medical degree from Yale University in New Haven, Conn. After completing his clinical fellowship training in infectious diseases, he remained at Yale as assistant and then associate professor until 1986. In 1986, Dr. Malech joined the NIH as a senior investigator at NIAID.

Financial terms:

Latest news:

Is general: Yes